ASCO 2017

ASCO 2017

Published on 21 June 2017

Edison attended the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US, on 2-6 June. This year the main focus was chimeric antigen receptor (CAR) T Cell therapies, in particular CARTs targeting BCMA from Bluebird Bio and Nanjing Legend; and immuno-oncology (IO) combinations such as IDO1/PD-1 inhibitors and new targets like LAG3 and GITR. Targeted therapies also took centre stage, particularly Loxo’s larotrectinib and AstraZeneca’s Lynparza, along with Roche’s APHINITY data. Finally, we also present data from companies under our coverage: Hutchison China MediTech, MorphoSys, PharmaMar, Prima Biomed and Viralytics.

Download PDF


Equity risks are rising: economic surprises turning lower

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free